drugset / Trial / NCT04540107
Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
Phase 1
Recruiting
300 enrolled
Susan Chang
GE Healthcare · collabNational Cancer Institute (NCI) · collabPhillips-Medisize · collabSigma-Aldrich · collab
Non-randomizedSequentialOpen-labelDiagnostic
Summary
This trial studies how well serial magnetic resonance (MR) imaging and MR spectroscopic imaging work in characterizing lower grade glioma. Diagnostic procedures, such as MR imaging and MR spectroscopic imaging, may detect serial changes in lower grade glioma. This study may help researchers learn more about practical ways of evaluating and standardizing treatment in patients with brain tumors.
Timeline
- Start
- 2017-01-11
- Primary completion
- 2027-01-31
- Completion
- 2027-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hyperpolarized 13C-Pyruvate | Diagnostic / imaging agent | — | Intravenous |